5 Best Healthcare Technology Stocks To Own Right Now

Sterne Agee reported on Thursday that it has upgraded Tiffany & Co. (TIF) to “Buy.”

The firm has lifted its rating on TIF from “Neutral” to “Buy,” and has given the company a $86 price target. This price target suggests an 11% upside from the stock’s current price of $76.

An analyst from the firm noted: ��e are upgrading TIF to Buy. The company has a highly visible margin recapture opportunity over the next 18-24 months, a rapidly growing international platform (50% of sales comping HSD) and a US business that, while lagging the past 18 months, has recently made a number of key hires and implemented several new product initiatives that should lead to improving performance over the medium-term. The recent pullback has created a compelling entry point, and we see several ways to win from here.��/p>

Top 10 Asian Companies To Buy For 2016: Atossa Genetics Inc (ATOS)

Atossa Genetics Inc., incorporated on April 30, 2009, is a development-stage healthcare company focused on the prevention of breast cancer through the commercialization of diagnostic tests that can detect precursors to breast cancer, and through the research, development, and ultimate commercialization of treatments for pre-cancerous lesions. The Company�� diagnostic tests consist of medical devices cleared by the Food and Drug Administration (FDA), which can collect fluid samples from the breast milk ducts, where over 95% of breast cancers arise. During the fiscal year ended September 30, 2012, the tests that the Company offered and that are in development consist of ForeCYTE, ArgusCYTE, FullCYTE and NextCYTE. In September 2012, the Company acquired all of the assets of Acueity.

The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 73. The ArgusCYTE Breast Health Test provides information to help inform breast cancer treatment options and to help monitor potential recurrence. The FullCYTE Breast Health Test is designed to assess the individual breast ducts for pre-cancerous changes in women previously identified to be at high risk for breast cancer. The NextCYTE Breast Cancer Test is designed to profile breast cancer specimens for prediction of treatment outcomes and distant recurrence in women newly diagnosed with breast cancer. MASCT, Oxy-MASCT, and its name and logo are the trademarks. ForeCYTE, FullCYTE, NextCYTE, and ArgusCYTE are its service marks.

Advisors' Opinion:

• [By James E. Brumley]

  I have little doubt that what I'm about to say could inflame some fans and followers of Atossa Genetics Inc. (NASDAQ:ATOS). But, I wouldn't be doing my job if I didn't call 'em like I see 'em. So, here goes. ATOS is on the verge of a substantial meltdown. It's possible the stock could circumvent this pullback, but the odds don't favor it.

• [By Virginia Harrison]

  The other big Olympic sponsors are Visa (V, Fortune 500), Samsung (SSNLF), Panasonic (PCRFF), General Electric (GE, Fortune 500), Dow Chemical (DOW, Fortune 500), Procter & Gamble (PG, Fortune 500), Omega (OCFN) and Atos (ATOS). They're staying tight-lipped about the issue in public but a senior official at the International Olympic Committee said this month that several had raised concerns about how the law could affect the Games.

5 Best Healthcare Technology Stocks To Own Right Now: Seattle Genetics Inc.(SGEN)

Seattle Genetics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases in the United States. Its lead product, SGN-35 is in pivotal trial stage used for the treatment of patients with relapsed or refractory hodgkin lymphoma. The company?s other product candidates in various stages of clinical trials include SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; dacetuzumab (SGN-40), a humanized anti-CD40 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc .; Daiichi Sankyo Co., Ltd.; Genentech, Inc.; GlaxoSmithKline LLC; Millennium; and PSMA Development Company LLC. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc.; and Genmab A/S. Seattle Genetics, Inc. was founded in 1997 and is headquartered in Bothell, Washington.

Advisors' Opinion:

• [By Rich Bieglmeier]

  [Related -Seattle Genetics, Inc. (SGEN), Takeda Report Encouraging Data From ADCETRIS Study]

  Let's take a look at what $2 billion in ADCETRIS sales could mean for the stock price and where SGEN shares would need to trade to become a low-end large cap stock.

• [By Lee Jackson]

  While very upbeat on the sector as a whole, UBS was very cautious on sell-rated Ironwood Pharmaceuticals, Inc (NASDAQ: IRWD) and ImmunoGen Inc. (NASDAQ: IMGN). Neutral-rated Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) and Seattle Genetics Inc. (NASDAQ: SGEN) were also viewed with a skeptical eye.

• [By Henry Kawabe]

  One of the variables that differentiates SMDCs from another cancer treatment in development, like Seattle Genetics' (SGEN) antibody-drug conjugates (ADC), are that SMDCs are 100-150 times smaller than an antibody. These small conjugates are able to penetrate solid tumors more effectively than large molecules ADCs. In preclinical studies, Endocyte saw a 20 to 30 fold improvement in drug concentration inside solid tumors with small molecule drug conjugates compared to large molecule drug conjugates. The small size also demonstrated faster excretion, which helped to reduce the drug's toxicity.

5 Best Healthcare Technology Stocks To Own Right Now: Glacier Water Services Inc (GWSV)

Glacier Water Services, Inc. (Glacier) is primarily engaged in the operation of self-service vending machines that dispense drinking water to consumers. The machines are placed at supermarkets and other retail outlets under commission arrangements with the retailers. The Company�� machines are primarily located throughout the Sunbelt and Midwest regions of the United States.

As of January 2, 2011, the Company operated approximately 19, 100 machines in 42 states and Canada. Glacier�� indoor water vending machine was introduced especially for inside the retail store. In addition to having the same multi-stage filtration/treatment system as the outdoor machine, many retailers make available a supply of empty containers near the indoor machine. Glacier also operates a line of PureFill and Water Island equipment.

Advisors' Opinion:

• [By John Udovich]

  Small cap OTC drinking water stocks Glacier Water Services, Inc (OTCMKTS: GWSV), AWG International Water Corp (OTCBB: AWGI) and Alkaline Water Company Inc (OTCBB: WTER) all offer a product that many consumer, investors and traders alike might take for granted, but everyone needs to have. However, you can build a better mouse trap when it comes to drinking water or at least that what these three small caps are attempting to do with their own unique strategies:

5 Best Healthcare Technology Stocks To Own Right Now: U.S. Geothermal Inc. (HTM)

U.S. Geothermal, Inc. engages in the acquisition, development, and utilization of geothermal resources in the western region of the United States. It constructs and manages power plants that utilize geothermal resources to produce energy. The company operates two power plants, including the Raft River geothermal power project located in the Raft River area of southern Idaho; and a 3.6 MW operating geothermal power plant and approximately 30,734.21 acres of geothermal energy leases and certain ground water rights located north of Reno, Nevada. It also holds interests in the Neal Hot Springs project located in eastern Oregon, which is under construction; Raft River project with 10 parcels comprising 783.93 acres of fee land and 4,736.79 acres of contiguous leased geothermal rights located on private property in Cassia County, Idaho; and lease contracts for approximately 21,905 acres of land and geothermal rights located in the San Emidio Desert, Nevada. In addition, the comp any has a geothermal lease contract for Granite Creek assets comprising approximately 2,443 acres of land and geothermal water rights located in the northwestern Nevada; and owns a geothermal concession consisting of 24,710 acres located southwest of Guatemala City, the Republic of Guatemala. Further, it has a joint venture agreement for geothermal rights for 3,615 acres located in northwestern Nevada. U.S. Geothermal, Inc. was founded in 2002 and is based in Boise, Idaho.

Advisors' Opinion:

• [By Bryan Murphy]

  If traders are leery of wading into a U.S. Geothermal Inc. (NYSEMKT:HTM) position, that's understandable. HTM has been touted repeatedly for years, sometimes paying off for a while, but usually imploding before any rally has a chance to get going. That may be about to change, however. In fact, it may have already changed, of a would-be owner is willing to take a step back and look at U.S. Geothermal for what it is rather than what it isn't.

• [By Bryan Murphy]

  By most accounts, it's an all-American dream come true. U.S. Geothermal Inc. (NYSEMKT:HTM), working hard - for years - to make something out of nothing can finally see the light at the end of the tunnel. HTM has swung to a profit, and is strong enough now that it's probably going to remain in the black in perpetuity. Shareholders who got into U.S. Geothermal anytime during or after 2012 have finally been handsomely rewarded, with most of that reward materializing in just the past three weeks. Regardless of when an investor got into a position in HTM though, there's just one thing left to do at this point.... get out. Lock in your gain and walk away, at least for a little while.

• [By Bryan Murphy]

  It's fun to be right, particularly when it has to do with stock-picking. Sometimes though, being right can be a real pain in the @#$%. Case in point? U.S. Geothermal Inc. (NYSEMKT:HTM). It was only two days ago that yours truly deemed HTM was a good-looking "buy" for true long-termers. Then today happens... a 27% rally that should have wise investors - even those who stepped into U.S. Geothermal with a long-term mindset - at least thinking about locking in their profits and walking away with a quick score. After all, you can always buy HTM back later.